Journal
RHEUMATOLOGY
Volume 58, Issue -, Pages 7-16Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kez418
Keywords
checkpoint inhibitor; adverse event
Categories
Funding
- BMS
Ask authors/readers for more resources
Immunotherapy has an increasing role in the management of cancer, both in metastatic disease and as an adjuvant therapy. However, sensitization of the immune system with checkpoint inhibitors comes with a unique side effect profile. Full appreciation of this can take some time to emerge as some adverse events are rare, or can be subtle and potentially overlooked. Clinician awareness of these side effects can be particularly important in patients with pre-existing autoimmune conditions. Here we describe common symptoms and diagnostic strategies for organ-specific side effects of anti-CTLA-4 and anti-PD-1/PD-L1 immunotherapy agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available